• Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
• Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
• Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge
An innovative gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases, has been launched at the University of Sheffield in collaboration with the Cell and Gene Therapy Catapult.
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments. It follows five acquisitions made by the companies so far this year.
Cytena Bioprocess Solutions have recently launched their next generation microbioreactor, the S.NEST. This exceptional instrument features a patented mixing technology which creates an optimal suspension culture environment, as well as real-time monitoring of pH and dissolved oxygen, four individually controlled incubation chambers and sophisticated analytical software.
CPI Enterprises, the investor engagement and ventures arm of CPI, has made its first investment in Qualus, a cleantech firm working to reduce water and chemical consumption within the leather industry.
For our product development, we are interested in speaking to as many prospective users as possible.
All you need to do: Fill in this 3-minute survey.
And the best part? You'll get the chance to win a £50 Amazon voucher.
Deadline: July 30th 2021
Leading European law firm Fieldfisher has launched white paper titled 'the future of medicine: Cell and gene therapy', an insight into the regulatory landscape for advanced therapy medicinal products and the potential of cell and gene therapy in the UK and other key hotspots in Europe post-Covid.
Sandwich, Kent, July 21 2021 – Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, is pleased to announce the launch of its first Reactor programme to drive the development of life sciences firms in the UK.
Edinburgh based Firefinch Software is delighted to announce that its Head of Marketing Sophie Read was the winner of a special recognition award for outstanding contribution to STEM education in the North East STEM Awards held virtually on the 15th July.
Chief.AI, in partnership with Medicines Discovery Catapult (MDC), has launched the first no-code, pay as you go, AI platform for drug discovery – offering greater access to AI and data in the areas of drug discovery, diagnostics and clinical trials.